Don’t get Nathan Jones started on xylitol, the active ingredient in his chewing gum, nasal spray, and other products. He’ll talk your ear off about its wondrous powers against tooth decay, as well as its potential to fight covid, heart disease, Alzheimer’s — you name it. For now, Jones, the founder of Xlear, can’t make…
As measles surged in Texas early this year, the Trump administration’s actions sowed fear and confusion among CDC scientists that kept them from performing the agency’s most critical function — emergency response — when it mattered most, an investigation from KFF Health News shows. The outbreak soon became the worst the United States has endured…
My friend Rosemarie Day joins me to talk about the Healthcare Leaders for Democracy session coming up on September 4 (Thursday) at 8pm ET 5pm PT. It’s a one hour session with Atul Gawande as the keynote speaker, joined by Don Berwick and John McDonough. It’ll be a fascinating discussion and it’s a fundraiser for…
Precigen’s Papzimeos is the first FDA-approved drug for the rare disease recurrent respiratory papillomatosis, or RRP. While this immunotherapy carries blockbuster expectations, Precigen’s financial reports indicate budgetary challenges. The post First Therapy for Rare Tumor Is a Blockbuster Prospect, But Does Precigen Have the Cash to Make It Happen? appeared first on MedCity News.
Many insurers seem to be retreating from Medicare Advantage by exiting unprofitable markets and reducing benefits. This could be extremely disruptive to patients, experts warn. The post Insurers are Pulling Back on MA. How Does this Affect Patients? appeared first on MedCity News.
Boston-based startup Cascala Health raised an $8.6 million seed round to expand its AI platform for risk-bearing providers. The platform is designed to make patient care transitions safer and more efficient, as well as to help care teams spot risks earlier. The post AI Meets Care Transitions: How One Startup Is Seeking to Reduce Readmissions…
Approval is only the beginning. Now comes the harder part: identifying the right patients, detecting the disease earlier, and monitoring outcomes so that this promising treatment is effective at scale. The post After Wegovy’s Historic MASH Approval, What’s Next? appeared first on MedCity News.
His longstanding anti-vaccine rhetoric and vocal opposition to science-backed expert consensus has caused widespread concern among public health and medical professionals about the appropriateness of his leadership. The post Secretary Kennedy’s Pride and Prejudice appeared first on MedCity News.
Develop Health’s Series A funding round was led by Wing Venture Capital, and included participation from Afore Capital, J Ventures and South Park Commons. The post Develop Health Secures $14.3M to Streamline Prior Authorization appeared first on MedCity News.
The FDA approved Ionis Pharmaceuticals’ Dawnzera for preventing swelling attacks caused by the rare disease hereditary angioedema. A Takeda Pharmaceutical product dominates this market, but Ionis has clinical data showing patients had better outcomes after switching to Dawnzera from Takeda’s drug and other currently available HAE medications. The post In Crowded Market for a Rare…